Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays

Clinical Microbiology and Infection

Volumn 16, Issue 10, 2010, Pages 1525-1531

  Peeters, M ^a   Aghokeng, A F ^b   Delaporte, E ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b Institut de Recherche pour le Developpement Cameroon   (Cameroon)

Author keywords

Drug resistance test; Genetic diversity; HIV 1; Review; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; COST UTILITY ANALYSIS; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE SEQUENCE; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; MUTATIONAL ANALYSIS; NONHUMAN; PANDEMIC; PATIENT MONITORING; PHYLOGENETIC TREE; POINT MUTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; VIRUS CLASSIFICATION; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77957045363     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03300.x     Document Type: Review

References (68)

1. Robertson DL, Anderson JP, Bradac JA. Hiv-1 nomenclature proposal. Science 2000, 288:55-56.
2. Butler IF, Pandrea I, Marx PA, Apetrei C. HIV genetic diversity: biological and public health consequences. Curr HIV Res 2007, 5:23-45.
3. Hahn BH, Shaw GM, De Cock KM, Sharp PM. Aids as a zoonosis: scientific and public health implications. Science 2000, 287:607-614.
4. Keele BF, Van Heuverswyn F, Li Y. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313:523-526.
5. Van Heuverswyn F, Li Y, Neel C. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006, 444:164.
6. Santiago ML, Range F, Keele BF. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Tai forest, Cote d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J Virol 2005, 79:12515-12527.
7. Vergne L, Bourgeois A, Mpoudi-Ngole E. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between si-inducing phenotype of the predominant crf02_ag variant and disease stage. Virology 2003, 310:254-266.
8. Vessiere A, Leoz M, Brodard V. First evidence of a HIV-1 m/o recombinant form circulating outside Cameroon. AIDS 2010, 24:1079-1082.
9. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20:W13-W23.
10. Peeters M, Sharp PM. Genetic diversity of HIV-1: the moving target. AIDS 2000, 14:S129-S140.
11. Vidal N, Peeters M, Mulanga-Kabeya C. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J Virol 2000, 74:10498-10507.
12. Zhu T, Korber BT, Nahmias AJ, Hooper E, Sharp PM, Ho DD. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998, 391:594-597.
13. Worobey M, Gemmel M, Teuwen DE. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008, 455:661-664.
14. Peeters M, Toure-Kane C, Nkengasong JN. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 2003, 17:2547-2560.
15. McCutchan FE. Global epidemiology of HIV. J Med Virol 2006, 78(suppl 1):S7-S12.
16. Wheeler WH, Ziebell RA, Zabina H. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010, 24:1203-1212.
17. Fleury H, Recordon-Pinson P, Caumont A. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res Hum Retroviruses 2003, 19:41-47.
18. Tatt ID, Barlow KL, Clewley JP, Gill ON, Parry JV. Surveillance of HIV-1 subtypes among heterosexuals in England and Wales, 1997-2000. J Acquir Immune Defic Syndr 2004, 36:1092-1099.
19. Couturier E, Damond F, Roques P. HIV-1 diversity in France, 1996-1998. The ac 11 laboratory network. AIDS 2000, 14:289-296.
20. Peeters M, Liegeois F, Torimiro N. Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. J Virol 1999, 73:7368-7375.
21. Aids epidemic update. http://dataunaidsorg/pub/Report/2009/2009_epidemic_update_enpdf, Available at: (last accessed 2 June 2010)
22. Apetrei C, Loussert-Ajaka I, Descamps D. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS 1996, 10:F57-F60.
23. Loussert-Ajaka I, Ly TD, Chaix ML. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994, 343:1393-1394.
24. Aghokeng AF, Mpoudi-Ngole E, Dimodi H. Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS ONE 2009, 4:e7702.
25. Corcoran C, Hardie D. HIV-1 subtype C seronegative AIDS. Clin Infect Dis 2008, 46:322-323.
26. Gautheret-Dejean A, Mesmin-Poho S, Birguel J, Lemee V, Huraux JM, Plantier JC. Unequal detection of HIV type 1 group O infection by simple rapid tests. Clin Infect Dis 2008, 46:1936-1937.
27. Novitsky V, Gaolathe T, Woldegabriel E, Makhema J, Essex M. A seronegative case of HIV-1 subtype C infection in Botswana. Clin Infect Dis 2007, 45:e68-e71.
28. Holodniy M. HIV-1 load quantitation: a 17-year perspective. J Infect Dis 2006, 194(suppl 1):S38-S44.
29. Plantier JC, Gueudin M, Damond F, Braun J, Mauclere P, Simon F. Plasma RNA quantification and HIV-1 divergent strains. J Acquir Immune Defic Syndr 2003, 33:1-7.
30. Wittek M, Sturmer M, Doerr HW, Berger A. Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev Mol Diagn 2007, 7:237-246.
31. Stevens WS, Noble L, Berrie L, Sarang S, Scott LE. Ultra-high-throughput, automated nucleic acid detection of human immunodeficiency virus (HIV) for infant infection diagnosis using the Gen-Probe APTIMA HIV-1 screening assay. J Clin Microbiol 2009, 47:2465-2469.
32. Alaeus A, Lidman K, Sonnerborg A, Albert J. Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS 1997, 11:859-865.
33. Gottesman BS, Grosman Z, Lorber M. Measurement of HIV RNA in patients infected by subtype C by assays optimized for subtype B results in an underestimation of the viral load. J Med Virol 2004, 73:167-171.
34. Gueudin M, Plantier JC, Damond F, Roques P, Mauclere P, Simon F. Plasma viral RNA assay in HIV-1 group O infection by real-time PCR. J Virol Methods 2003, 113:43-49.
35. Loussert-Ajaka I, Descamps D, Simon F, Brun-Vezinet F, Ekwalanga M, Saragosti S. Genetic diversity and HIV detection by polymerase chain reaction. Lancet 1995, 346:912-913.
36. Parekh B, Phillips S, Granade TC, Baggs J, Hu DJ, Respess R. Impact of HIV type 1 subtype variation on viral RNA quantitation. AIDS Res Hum Retroviruses 1999, 15:133-142.
37. Swanson P, de Mendoza C, Joshi Y. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: Lcx HIV RNA quantitative, Amplicor HIV-1 Monitor v1.5, Versant HIV-1 RNA 3.0, and Nuclisens HIV-1 QT. J Clin Microbiol 2005, 43:3860-3868.
38. Triques K, Coste J, Perret JL. Efficiencies of four versions of the Amplicor HIV-1 monitor test for quantification of different subtypes of human immunodeficiency virus type 1. J Clin Microbiol 1999, 37:110-116.
39. Rouet F, Chaix ML, Nerrienet E. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence nationale de recherches sur le sida second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007, 45:380-388.
40. Pas S, Rossen JW, Schoener D. Performance evaluation of the new Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA. J Clin Microbiol 2010, 48:1195-1200.
41. Scott L, Carmona S, Stevens W. Performance of the new Roche COBAS AmpliPrep-COBAS TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol 2009, 47:3400-3402.
42. Scott LE, Noble LD, Moloi J, Erasmus L, Venter WD, Stevens W. Evaluation of the Abbott m2000 realtime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche COBAS AmpliPrep-Cobas Amplicor, Roche COBAS AmpliPrep-COBAS TaqMan HIV-1, and bioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol 2009, 47:2209-2217.
43. Tang N, Huang S, Salituro J. A realtime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods 2007, 146:236-245.
44. Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med 2005, 13:138-142.
45. Hertogs K, de Bethune MP, Miller V. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
46. Kellam P, Larder BA. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994, 38:23-30.
47. Holguin A, Hertogs K, Soriano V. Performance of drug resistance assays in testing HIV-1 non-B subtypes. Clin Microbiol Infect 2003, 9:323-326.
48. Tong CY, Mullen J, Kulasegaram R, De Ruiter A, O'Shea S, Chrystie IL. Genotyping of B and non-B subtypes of human immunodeficiency virus type 1. J Clin Microbiol 2005, 43:4623-4627.
49. Eshleman SH, Hackett J, Swanson P. Performance of the Celera Diagnostics ViroSeq HIV-1 genotyping system for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol 2004, 42:2711-2717.
50. Grant RM, Kuritzkes DR, Johnson VA. Accuracy of the Trugene HIV-1 genotyping kit. J Clin Microbiol 2003, 41:1586-1593.
51. Leitner T, Halapi E, Scarlatti G. Analysis of heterogeneous viral populations by direct DNA sequencing. BioTechniques 1993, 15:120-127.
52. Schuurman R, Brambilla D, de Groot T. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 2002, 18:243-248.
53. Xiao L, Zhang J, Yin YF. Molecular diagnosis of HIV and relevant novel technologies in mutation analysis. Biotechnol Adv 2008, 26:389-397.
54. Eshleman SH, Crutcher G, Petrauskene O. Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI Prism 3100 genetic analyzer. J Clin Microbiol 2005, 43:813-817.
55. Maes B, Schrooten Y, Snoeck J. Performance of ViroSeq HIV-1 genotyping system in routine practice at a Belgian clinical laboratory. J Virol Methods 2004, 119:45-49.
56. Wallis CL, Papathanasopoulos MA, Lakhi S. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 2010, 163:505-508.
57. Beddows S, Galpin S, Kazmi SH. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J Med Virol 2003, 70:337-342.
58. Jagodzinski LL, Cooley JD, Weber M, Michael NL. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J Clin Microbiol 2003, 41:998-1003.
59. Vergne L, Peeters M, Mpoudi-Ngole E. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000, 38:3919-3925.
60. Monleau M, Plantier JC, Peeters M. HIV contamination of commercial PCR enzymes raises the importance of quality control of low-cost in-house genotypic HIV drug resistance tests. Antivir Ther 2010, 15:121-126.
61. Vergne L, Snoeck J, Aghokeng A. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol 2006, 46:53-62.
62. Snoeck J, Kantor R, Shafer RW. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006, 50:694-701.
63. Pieniazek D, Rayfield M, Hu DJ. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV variant working group. AIDS 2000, 14:1489-1495.
64. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009, 12:11.
65. Shi C, Eshleman SH, Jones D. Ligamp for sensitive detection of single-nucleotide differences. Nat Methods 2004, 1:141-147.
66. Beck IA, Mahalanabis M, Pepper G. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol 2002, 40:1413-1419.
67. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol 1998, 36:569-572.
68. Wallis CL, Mahomed I, Morris L. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J Virol Methods 2005, 125:99-109.